剔除新成立的基金，公募市场披露存续的300余只QDII基金产品（初始基金口径，下同）2025年7月平均回报率为3.95%。 数据显示，7月份，华泰柏瑞恒生创新药ETF、易方达全球医药行业人民币A等QDII基金表现居前，大多和港股医药等资产配置相关。 另一方面，宏利印度、华安三菱日联日经225ETF联接A、广发全球医疗保健A人民币等40余只基金7月净值出现回撤。 统计显示，剔除新成立的基金，公募市场披露存续的300余只QDII基金产品2025年7月平均回报率为3.95%。 图2：易方达全球医药行业人民币A7月净值走势 主动权益基金方面，易方达全球医药行业人民币A7月表现居前，收益率达到27.47%。基金经理在二季报中称："报告期内，本基金继续看好中国医药行业 尤其是创新药相关公司的表现，维持在该方向上的配置仓位，并自下而上精选个股进行优化;同时，考虑到海外医药股受到美国政府医药关税、MFN(最惠 国待遇)等政策不确定性影响，因此降低了美股仓位。"该基金2025二季度末重仓信达生物、映恩生物、三生制药等。 此外，汇添富香港优势精选A、南方港股医药行业A等主动权益基金在7月收益率同样居前。 中长期业绩方面，截至7月 ...

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]

Core Insights - The QDII fund market has seen significant growth, with a total scale of 582.37 billion and 312 products as of June 30, 2025, driven by domestic investors' increasing demand for overseas asset allocation [1] - There is a notable performance divergence among QDII funds in the first half of 2025, with Hong Kong and global pharmaceutical theme funds leading the performance rankings, while Southeast Asian technology, oil, and related regional theme products faced adjustment pressures [1][5] Performance Summary Top Performing QDII Funds - The top ten QDII funds in terms of returns are all focused on the pharmaceutical and biotechnology sectors, with the leading fund, 汇资高香港优势精选A, achieving a return of 86.48% [2][3] - Other notable performers include 广发中证香港创新药ETF with a 57.12% return and 华泰柏瑞恒生创新药ETF with a 56.94% return [2][3] - Smaller funds also showed strong performance, such as 工银新经济人民币 with a return of 52.92% despite a small scale of 0.45 billion [3] Underperforming QDII Funds - The bottom ten QDII funds primarily consist of Southeast Asian technology ETFs, with 华泰相瑞商力乐央新交所之东南亚科技ETF experiencing a decline of 11.66% [4][5] - Oil-themed funds also faced pressure, with 易方达原油A人民币 and 南方原油A both showing declines exceeding 5% [5] - Regional theme funds showed significant divergence, with two Saudi Arabian ETFs declining over 7%, indicating pressure from sovereign fund reductions [6] Market Outlook - Analysts believe that the Hong Kong market still offers investment value, with a focus on high-quality companies that can withstand economic cycles and dividend assets in a low-interest-rate environment [6] - There is an expectation of continued foreign capital inflow into Chinese assets as corporate earnings recover, supported by improved fundamentals and market share gains [6]

Core Viewpoint - The QDII funds have shown remarkable performance in the first half of 2025, with equity products achieving net value growth rates close to 90%, driven by strong rebounds in the Hong Kong stock market, particularly in sectors like innovative drugs, new consumption, and technology [1][2]. QDII Fund Performance - As of June 26, 2025, the average net value growth rate of 312 equity QDII funds was 12.5%, with top performers primarily in the innovative drug and biopharmaceutical sectors [3]. - The fund managed by Zhang Wei, Huatai-PB Hong Kong Advantage Selection A, led the market with a net value growth rate of 89.15% [3]. - Other notable funds include Huatai-PB Hang Seng Innovative Drug ETF and GF CSI Hong Kong Innovative Drug ETF, both exceeding 54% growth [3]. Market Drivers - The strong performance of QDII funds is attributed to the robust performance of the Chinese market, particularly the significant rise in stock prices of Hong Kong internet technology companies [3]. - The Chinese macroeconomic landscape has shown signs of stabilization, with no significant negative impacts from tariff policies, and a trend of upward reversal in the fundamentals of the technology sector [3][4]. Investment Opportunities - Looking ahead to the second half of 2025, there are significant investment opportunities in Hong Kong stocks, especially in leading companies within the internet, innovative drugs, and new consumption sectors [5][6]. - The Hong Kong stock market is seen as being in a value recovery phase, with many high-quality companies successfully expanding globally, which has not yet been fully priced in [6]. Sector Focus - The technology sector in Hong Kong is highlighted as a key area for investment, driven by the macroeconomic narrative of asset revaluation and the rise of the Chinese technology industry [7]. - The Hang Seng Technology Index is characterized by low valuations and high growth potential, with expectations of strong earnings growth for its constituent companies [8]. Global Market Insights - There is a positive outlook for the US stock market, particularly in the technology sector, supported by a clearer shift in monetary policy and favorable fiscal signals [8][9]. - Key factors for the US market include anticipated interest rate cuts, easing financial regulations, and a manageable risk environment in the bond market [8][9]. Regional Opportunities - Investment managers are focusing on three main areas for the second half: the US technology sector, gold as a hedge against geopolitical changes and a weakening dollar, and regional opportunities in East and Southeast Asia [9].

Core Viewpoint - QDII funds have shown remarkable performance in 2025, with the highest growth rate nearing 90%, driven by strong rebounds in the Hong Kong stock market, particularly in sectors like innovative pharmaceuticals, new consumption, and technology [1][2]. Summary by Sections QDII Fund Performance - As of June 26, 2025, the average net value growth rate of 312 equity QDII funds is 12.5%, with top performers primarily in innovative pharmaceuticals and biotechnology [3]. - The fund managed by Zhang Wei, Huatai-PB Hong Kong Advantage Selection A, leads with a net value growth rate of 89.15%, followed by several other funds with growth rates exceeding 54% [3]. Market Drivers - The strong performance of QDII funds in the first half of the year is attributed to the robust performance of the Chinese market, particularly the significant rise in stock prices of Hong Kong internet technology companies [4]. - The Chinese macroeconomic landscape shows signs of stabilization, with the technology sector experiencing a trend reversal, aided by breakthroughs in AI technology [4]. Investment Opportunities - Looking ahead to the second half of the year, there are significant investment opportunities in Hong Kong stocks, especially in internet, new consumption, and innovative pharmaceutical sectors [7]. - The Hong Kong stock market is seen as being in a value recovery phase, with many high-quality companies yet to be fully priced in [7]. Focus on Technology and Pharmaceuticals - The investment focus for the second half includes Hong Kong technology stocks, driven by the narrative of asset revaluation and the rise of the Chinese technology sector [8]. - The Hang Seng Technology Index is characterized by low valuations and high growth potential, with expectations of strong earnings growth for its constituent companies [8]. U.S. Market Outlook - There is a relatively optimistic outlook for the U.S. market, particularly in the technology sector, supported by favorable monetary and fiscal policies [9]. - Key factors include a clear shift in the monetary policy cycle, positive fiscal signals, and manageable risks in the U.S. bond market [9]. Additional Investment Areas - Key areas of focus for the second half include U.S. technology, gold, and regional opportunities in East Asia and Southeast Asia, driven by a weaker dollar and liquidity premiums [10].